Protease Inhibitor class drugs

8 results

  • Evotaz

    (atazanavir and cobicistat)
    E.R. Squibb & Sons, L.L.C.
    Usage: EVOTAZ® is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents for adults and pediatric patients weighing at least 35 kg. Its use in treatment-experienced patients should be guided by baseline protease inhibitor resistance.

  • Norvir

    (Ritonavir)
    AbbVie Inc.
    Usage: NORVIR is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents in adults and pediatric patients.

  • Paxlovid

    (nirmatrelvir and ritonavir)
    Pfizer Laboratories Div Pfizer Inc
    Usage: PAXLOVID is indicated for the treatment of mild-to-moderate COVID-19 in adults at high risk for severe disease progression, including hospitalization or death. It is not approved for COVID-19 prevention via pre-exposure or post-exposure prophylaxis.

  • Prezcobix

    (DARUNAVIR ETHANOLATE and COBICISTAT)
    Janssen Products LP
    Usage: PREZCOBIX is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents for both treatment-naïve and treatment-experienced adults and pediatric patients (weighing at least 40 kg) without specific darunavir resistance mutations.

  • Prezcobix

    (DARUNAVIR ETHANOLATE and COBICISTAT)
    A-S Medication Solutions
    Usage: PREZCOBIX is indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥40 kg), either treatment-naïve or experienced, when used with other antiretroviral agents and in the absence of specific darunavir resistance-associated substitutions.

  • Prezista

    (darunavir)
    Janssen Products LP
    Usage: PREZISTA, when co-administered with ritonavir and other antiretroviral agents, is indicated for the treatment of HIV-1 infection in adults and pediatric patients aged 3 years and older.

  • Reyataz

    (ATAZANAVIR)
    E.R. Squibb & Sons, L.L.C.
    Usage: REYATAZ® is indicated for the treatment of HIV-1 infection in adults and pediatric patients aged 3 months and older who weigh at least 5 kg, in combination with other antiretroviral agents. It is not recommended for patients under 3 months due to the risk of kernicterus.

  • Symtuza

    (Darunavir, Cobicistat, Emtricitabine, and Tenofovir alafenamide)
    Janssen Products LP
    Usage: SYMTUZA is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg, either as a complete regimen for those with no prior antiretroviral treatment history or for those who are virologically suppressed on a stable regimen for at least 6 months.